Expression And Clinical Significance Of BMI-1in Endometrial Carcinoma

Objective: We will analysis the relationships of BMI-1and endometrial carcinomain surgical-pathologic staging、pathological type、histology sizing、infiltrating depth ofmuscular layer、corestriction of lymphoid knot and estrogen or progeserone receptor andrelativity of it is each factor to study and research the role of BMI-1play in occurrence、development、infiltrating and corestriction in endometrial carcinoma and it is guidancemeaning of clinical diagnosis、treatment and prognostic．Methods： We are selected the endometrium from hysterectomy patients andhysteroscopy in patients of the second clinical hospital of Jilin university from may2010tomarch2011.15patients are normal endometrium (8cases are proliferative endometrium,7cases are secretory endometrium);20cases are endometrial hyperplasia disease (endometrialsimple hyperplasia10cases,endometrial complex hyperplasia5cases,endometrialhyperplasia of atypical5cases);42patients are endometrial carcinoma:according to thesurgical-pathologic staging of the Federation International of Gynecology and Obstetrrics（FIGO2009）standard for staging,phase I,28cases;phase II,7cases;phase III-Ⅳ,7case.Histology sizing:high differentiation（G1period）,17cases;moderate differentiation（G2period）,14cases;low differentiation（G3period）,11cases.6patients are corestriction oflymphoid knot,36patients are not. All the specimens are diagnosed in pathology departmentof the second clinical hospital of Jilin university, not accepting preoperative chemotherapy、taking drug therapy and sex hormones. Immunohistochemistry is used to detect theexpression of BMI-1in various tissues. we analysis the relationships of BMI-1andendometrial carcinocma in surgical-pathologic staging、pathological type、histology sizing、infiltrating depth of muscular layer、 corestriction of lymphoid knot and estrogen orprogeserone receptor and relativity of it is each factor to study and research the role ofBMI-1play in occurrence、development、infiltrating and corestriction in endometrialcarcinoma. All datas are treated by statistical analysis.The statistically significant level is P＜0.05.Result: (1): The respective average gray value of BMI-1in normal endometrium、Endome-trial hyperplasia disease and endometrial carcinoma is:199.47±9.151、143.60±9.361、106.31±11.696. The expression of BMI-1in endometrial adenocarcinoma is significantlyhigher than normal endometrial and endometrial hyperplasia disease (P <0.05); Theexpression of BMI-1in endometrial hyperplasia is the same higher than normal endometrialtissue (P <0.05).(2):The respective average gray value of BMI-1in endometrial carcinoma FIGOstageⅠ、Ⅱ、Ⅲ-Ⅳ is112.21±6.994、102.57±8.0778、86.42±3.207.The expression ofBMI-1in stage Ⅲ-Ⅳ is obviously higher than stage II (P <0.01),The expression of BMI-1in stage Ⅱ has higher than stage I (P <0.01).(3):The respective average gray value of BMI-1in the group lymph node metastasisand not lymph node metastasis is86.83±3.311、109.56±9.100.The expression of BMI-1inthe group lymph node metastasis is significantly higher than not metastasis tissues.(4): The respective average gray value of BMI-1in less than or equal to1/2ofinfiltrating depth of muscular layer and more than1/2of infiltrating depth of muscular layeris112.86±7.539、109.20±1.923.The expression of BMI-1in less than or equal to1/2ofinfiltrating depth of muscular layer is higher than more than1/2of infiltrating depth ofmuscular layer(P <0.01).(5): The respective average gray value of BMI-1in high、medium、low differentiatedendometrial cancer is108.76±12.700、104.50±8.609、104.40±14.001. The expression ofBMI-1in each differentiated endometrial has no significant difference (P>0.05).(6): The respective average gray value of BMI-1in endometrial adenocarcinoma andother types of cancer is107.08±10.5572、99.00±18.565. The expression of BMI-1in eachgroup has no significant difference BMI-1(P>0.05).(7): The respective average gray value of BMI-1in estrogen or progeserone receptorpositive and in estrogen or progeserone receptor negative is106.86±10.687、105.70±12.970. The expression of BMI-1in each group has no significant difference BMI-1(P>0.05).Conclusion: The expression of BMI-1in endometrial carcinoma tissues is patency higher than it is in normal endometrium tissues and atypical hyperplasia tissues，and atypicalhyperplasia tissues is higher than normal endometrium tissues, The expression of BMI-1inthe endometrial carcinoma was advanced with the heighten of surgical-pathologic staging、deeper of muscular layer infiltrating and occurrence of lymphoid knot corestriction，but it isnothing to do with Pathology type、 histology sizing and estrogen or progeseronereceptor．BMI-1is closely relevant with the occurrence、development、infiltrating andcorestriction of endometrial carcinoma. With the development of targeted therapy，BMI-1may become biological parameter of endometrial carcinoma to clinical diagnosis、therapeutics direction、evaluate prognostic and new molecule of gene therapy．...